ARF1 and cancer: Importantly, prior work in other cancer models has shown that azelastine can directly bind ARF1 (DARTS-based target identification and SPR with low-nanomolar Kd; loss of binding in an ARF1 mutant), which is mechanistically congruent with our ARF1-dependency and GCA rescue in TNBC.